Beroctocog alfa

Drug Profile

Beroctocog alfa

Alternative Names: GC 1101; GC 1101C; GC1101 D; GreenGene F; r-FVIII - Green Cross; Recombinant factor VIII - Green Cross

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Haemophilia A

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 22 Aug 2017 Beroctocog alfa is available for licensing as of 22 Aug 2017.
  • 22 Aug 2017 Phase-III clinical trials in Haemophilia A in China (IV) before August 2017 (Green Cross pipeline, August 2017)
  • 23 Dec 2013 Green Cross Corporation initiates enrolment in a phase III extension trial for Haemophilia A (In adolescents, In adults) in United Kingdom and USA (EudraCT2013-004383-62)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top